Targeted Cancer Immune Therapy
Springer-Verlag New York Inc.
978-1-4939-3991-6 (ISBN)
Role of IL12 Family in Regulation of Antitumor Immune Response.- IL-18 in Regulation of Antitumor Immune Response and Clinical Application.- Interleukin-21 and Cancer Therapy.- IL-24 in Regulation of Antitumor Immune Response and in Signaling.- IL-28 and IL-29 in Regulation of Antitumor Immune Response and Induction of Tumor Regression.- Passive and Active Tumor Homing Cytokin Therapy.- New Strategies to Improve Tumor Cell Vaccine Therapy.- Modification of Dendritic Cells to Enhance Cancer Vaccine Potency.- Dendritic Cell Vaccines for Immunotherapy of Cancer: Challenges in Clinical Trials.- A Toll Bridge for T-Cells.- Engineering Adult Stem Cells for Cancer Immunotherapy.- Animal Models for Evaluating Immune Responses of Human Effector Cells in Vivo.- CD40 Stimulation and Antitumor Effects.- Immunocytokines: A Novel Approach to Cancer Immune Therapy.- Immune Escape: Role of Ondoleamine 2,3-Dioxygenase in Tumor Tolerance.- Adoptive Transfer of T-Bodies: Towards an Effective Cancer Immunotherapy.- Targeting Toll Like Receptor for the Induction of Immune and Antitumor Responses.- Manipulating TNF Receptors to Enhance Tumor Immunity for the Treatment of Cancer.-
Erscheinungsdatum | 11.06.2016 |
---|---|
Zusatzinfo | 7 Tables, black and white; XI, 343 p. |
Verlagsort | New York |
Sprache | englisch |
Maße | 155 x 235 mm |
Gewicht | 734 g |
Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie |
Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie | |
Medizin / Pharmazie ► Studium | |
ISBN-10 | 1-4939-3991-2 / 1493939912 |
ISBN-13 | 978-1-4939-3991-6 / 9781493939916 |
Zustand | Neuware |
Haben Sie eine Frage zum Produkt? |
aus dem Bereich